For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Enters Into Clinical Collaboration Agreement in Japan for Anticoagulant Reversal Agent Andexanet Alfa

Tokyo, Japan (April 5, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. (hereafter, Portola) to develop andexanet alfa in Japan as an anticoagulant reversal agent for Daiichi Sankyo's Factor Xa inhibitor, LIXIANA® (edoxaban).

Andexanet alfa is being developed as an anticoagulant reversal agent for patients treated with Factor Xa inhibitors, such as LIXIANA®, and has been submitted for Biologics License Application (BLA) approval as a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy.

Anti-coagulation therapy reversal agents are being developed for instances when the reversal of anticoagulation activity is needed, such as for life-threatening or uncontrolled bleeding or emergency surgery and urgent procedures; however, there is currently no agent that specifically reverses the anticoagulant effects of Factor Xa inhibitors.

Under this agreement, Daiichi Sankyo will work with Portola to develop andexanet alfa in Japan as a reversal agent for LIXIANA® as we strive to maximize its product value.